Liquid cancer treatment market growth Generally known as blood-based cancers, liquid cancers are most formally known as leukemia, myeloma and lymphoma and start in the bone marrow, where blood is produced. Broadly speaking, the global blood cancer drug market is expected to reach a valuation of $108 billion by 2031, with the increasing prevalence of blood cancer driving that growth. Internationally, approximately 474,519 new cases of leukemia were reported in 2020, with the global leukemia treatment market expected to reach $27.78 billion by 2027. Among the several types of leukemia, some occur most often in children, while others most often in adults. Acute myeloid leukemia, chronic myelogenous leukemia and chronic lymphocytic leukemia most often occur in adults, while acute lymphocytic leukemia occurs in all age groups. The myeloma treatment market is expected to reach $USD 31 billion by 2026 growing at a CAGR of 6 per cent. Multiple myeloma is a rare form of cancer and is one of the types of blood cancer that accounts for a large prevalence of cancer cases, worldwide. As a result, this is leading to a higher number of diagnoses in patients; thus, gaining the attention of major market pharmaceutical players. When it comes to the lymphoma market, its treatment size is expected to reach $13.1 billion by 2026. Lymphoma is one of the most common forms of blood cancer, which means its market potential is significant. As such, new drug candidates are being evaluated in clinical studies to treat several forms of lymphoma.
Theralase® future outlook Theralase® notched a U.S. patent in October 2022, protecting the same technology as its newly acquired patent in Canada, while a European Union patent is currently pending. In its pipeline, the company is conducting a late-stage Phase II registration clinical study for bladder cancer, expected to be completed by 2026. Theralase® expects to launch a Phase Ib clinical study for brain cancer and lung cancer in 2024, pending the completion of a GLP toxicology analysis.
Theralase® investment corner Thanks to its robust pipeline, Theralase® has the potential to address a much-needed market with its next standard of care treatments for solid tumours, as well as blood-based cancers. As the company moves forward with clinical studies into 2024 and beyond, investors will no doubt be keenly watching how the company disrupts the pharmaceutical market. Join the discussion: Find out what everybody's saying about this stock on the Theralase® Technologies Bullboard investor discussion forum, and check out the rest of Stockhouse's stock forums and message boards. |